Genetics

This post covers Alwahsh and colleagues' 2024 Scientific Reports study, which used cryogenic proton NMR to quantify 40 serum metabolites in 30 relapsing-remitting, 30 primary progressive, and 30 secondary progressive MS patients against 30 controls. It reports the 25 metabolites separating patients from controls and the three reaching areas under the curve above 0.9, explains why those values are optimistic without a held-out set, notes the absent multiple-testing correction and which results it would remove, walks through the three-way subtype comparison, distinguishes cross-sectional subtype differences from progression, and flags two internal reporting inconsistencies and the narrow spread of the control group.